Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.
Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.
Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
NanoBio Corporation today announced a licensing agreement with the National Institutes of Health (NIH) that represents a significant step forward in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections.
NanoBio Corporation announced today that data from its ferret influenza vaccine study of NB-1008 have been published in the July 2011 issue of Clinical Vaccine Immunology by the American Society of Microbiology.
PharmAthene, Inc. announced today that it has achieved an important program milestone in its recombinant protective antigen (rPA) anthrax vaccine program and demonstrated 36 month stability of its rPA drug product candidate previously produced at Avecia Biologics Laboratories in the United Kingdom. The stability data were prepared utilizing a variety of analytical methods and a well characterized mouse challenge potency assay.
Researchers from the Smiley lab at the Trudeau Institute have now identified a single component of the plague causing bacterium that can be used as a vaccine. This single "subunit" could potentially be used to create a safer form of a T cell-stimulating plague vaccine. The new data is featured in the July issue of The Journal of Immunology.
Anthrax, septicemia and meningitis are some of the planet's most deadly infections. In part because doctors lack basic insights to prevent and cure diseases caused by so called Gram-positive bacteria. Now, a chemist from the University of Copenhagen has revealed the mechanism behind these deadly infections.
The U.S. Food and Drug Administration today approved the first generic versions of Levaquin, an antibiotic approved to treat certain infections in people ages 18 and older.
Scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have uncovered how the body's immune system launches its survival response to the notorious and deadly bacterium anthrax.
Aradigm Corporation today announced positive top line data from its recently concluded Phase 2b study (Once-Daily Respiratory Bronchiectasis Inhalation Treatment - ORBIT-1) with Aradigm's ciprofloxacin for inhalation (CFI, ARD-3100, LipoquinTM) in patients with non-cystic fibrosis bronchiectasis (BE).
Response Biomedical Corporation announced that it has received a notification from the U.S. Food and Drug Administration (FDA) that its NTproBNP Assay did not meet the criteria to obtain a waiver under the Clinical Laboratory Improvement Amendments of 1988.
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has entered into subscription agreements with certain institutional investors to sell approximately $6.5 million of its common stock and warrants in a registered direct offering.
Emergent BioSolutions Inc. announced today that its investigational anthrax vaccine, NuThrax, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA).
Aradigm Corporation today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ciprofloxacin for inhalation for the management of bronchiectasis (BE).
Emergent BioSolutions Inc. today announced that the U.S. government has indicated its intention to award Emergent a sole source contract (RFP-2011-N-13414) for the purchase of 44.75 million doses of BioThrax (Anthrax Vaccine Adsorbed) for inclusion in the Strategic National Stockpile (SNS) over a 5 year period.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced today that new pre-clinical data for its novel, defensin-mimetic antimicrobial compounds was recently presented at two prestigious scientific meetings, including the American Society of Microbiology.
The Trust for America's Health warns that cuts to the U.S. Centers for Disease Control and Prevention and other federal public health programs puts America's future health at risk.
Response Biomedical Corporation reported financial results for the first quarter ended March 31, 2011. Total revenues for the three-month period ended March 31, 2011 increased 59% to $2,470,560 compared to $1,549,479 for the same period last year.
An innovative way of making vaccines at the University of Central Florida has attracted the support of the Bill & Melinda Gates Foundation for its potential to make vaccines lessexpensive, more effective and needle free.
Researchers at the University of Illinois at Chicago's Center for Pharmaceutical Biotechnology have been awarded a federal contract for up to $13.8 million to develop antibiotics to treat anthrax, tularemia and plague.
AquaStar Holdings, Inc. is pleased to announce that the United States Patent and Trademark Office has issued patent number 7,708,944 for the Ultra-Sensitive, Portable Capillary Sensor technology utilized by the Capwave Enzyme-Linked Immuno-Sorbent Assay (ELISA) platform.
IQ Therapeutics has completed the dosing of antibody IQNLF in a Phase I clinical trial. A total of 36 healthy volunteers participated in the randomized, placebo controlled, double blind, single dose-escalating study, intended to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IQNLF.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.